Page 1 of 1 Attorney Docket No.: 25619-501

Modified Form 1449/PTO							Application Number 09/806,400						
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)							Filing Date March 30, 2001						
							First Named Inventor	Shoenfeld 1644 Ronald B. Schwadron					
							Group Art Unit						
							Examiner Name						
							Attorney Docket Number	25619-501					
× 7=		-				IIS	PATENT DOCUMENTS			-			
Exam Initials			.S. Patent ocument No.		Issue Date		Name of Patentee(s) or Applicant(s)		Sub Class	Filing Date If Appropriate			
					U.S. PUI	BLISH	HED APPLICATION DOCUMENTS	<u></u>	1	<u> </u>			
Exam Initials	Cite N	Cite No. U.S. Published Publish		Published Date			Class	Sub Class	Filing Date If Appropriate				
	L				F	OREI	GN PATENT DOCUMENTS			70	- 5		
			oreign Patent Document iffice Number			Name of Patentee(s) or Applicant(s)		Date of Publication		Translation Yes No			
	L						NON PATENT LITERATURE DOCUME			L	L		
Exam	Cite N												
Initials			Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.										
		Harats et al. "Antigen-Tailored Therapy Based on the Inflammat						Theory of A	theroscle	rosis",	Expert		
			Review of Vaccines, XP009118203, 3(5): 605-611, October 2004.										
			Shoenfeld "Autoantibodies Associated With Atherosclerosis", Annals of Medicine, XP009118 32(Suppl.1): 37-40, December 2000.)8,		
	-		European Patent Office, Supplementary European Search Report and the European Search Opinion								ion Re		
			Application No. 05788473.6. Dated 25 June 2009								on Re.		

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ______, filed _____, and relied upon for an earlier filing date under 35 U.S.C. § 120 (continuation, continuation-in-part, and divisional applications)

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.